LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box�, today released a statement from Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, regarding the Company�s recent listing on Nasdaq and the Company�s current business focus.